The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 01, 2022

Filed:

Mar. 23, 2020
Applicant:

National University Corporation Kumamoto University, Kumamoto, JP;

Inventors:

Yuichi Oike, Kumamoto, JP;

Tian Zhe, Kumamoto, JP;

Tsuyoshi Kadomatsu, Kumamoto, JP;

Keishi Miyata, Kumamoto, JP;

Haruki Horiguchi, Kumamoto, JP;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/11 (2006.01); A61K 48/00 (2006.01); C12Q 1/6883 (2018.01); A61K 31/713 (2006.01); A61K 31/7105 (2006.01); C12N 15/113 (2010.01); A61P 9/10 (2006.01); C12N 15/864 (2006.01);
U.S. Cl.
CPC ...
A61K 48/005 (2013.01); A61K 31/713 (2013.01); A61K 31/7105 (2013.01); A61P 9/10 (2018.01); C12N 15/11 (2013.01); C12N 15/113 (2013.01); C12N 15/8645 (2013.01); C12Q 1/6883 (2013.01); A01K 2217/05 (2013.01); A01K 2217/075 (2013.01); A01K 2227/105 (2013.01); A01K 2267/0375 (2013.01); C12N 2310/14 (2013.01); C12N 2750/14143 (2013.01); C12Q 2600/158 (2013.01);
Abstract

A pharmaceutical composition can be provide for treating or preventing heart failure. Additionally, siRNA and a vector expressing said siRNA can be provided that can be used in the pharmaceutical composition for treating or preventing heart failure. For example, a pharmaceutical composition can be provided for treating or preventing heart failure that contains a DNA sequence encoding RNA containing a sense strand sequence of consecutive 18 to 29 nucleotides from angiopoietin-like protein 2 (ANGPTL2) mRNA or the alternative splicing type RNA thereof and an antisense strand sequence complementary to the sense strand sequence under control of a promoter, and a pharmaceutically acceptable carrier.


Find Patent Forward Citations

Loading…